Lancet neurology
The most recent articles from:
Lancet Neurol
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment. ⋯ Merck & Co Inc.